EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieOpen Access · CC BY 4.0

A Comparison and Safety Evaluation of Micellar versus Standard Vitamin D3 Oral Supplementation in a Randomized, Double-Blind Human Pilot Study

Julia Solnier iD, Chuck Chang iD, Yiming Zhang, Yun Chai Kuo iD, Min Du iD, Yoon Seok Roh, Janet See, Jennifer Brix, Roland J Gahler, Tim Green, Simon Wood

Nutrients · 2024

DOI: 10.3390/nu16111573 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Nutrients, 2024. Verfasst von Julia Solnier und 10 weiteren Autor:innen. Beteiligte Einrichtung: ISURA, Clinical Research, Burnaby, BC V3N4S9, Canada. Hauptthemen laut MEDLINE: Cholecalciferol, Dietary Supplements, Micelles, Biological Availability. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Factors Group of Nutritional Companies provided a research grant for this study., Factors Group of Nutritional Companies.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The aim of this pilot study was to evaluate and compare bioavailability and safety of two Vitamin D3 formulations (softgels) in healthy adults, at single daily doses of 1000 and 2500 IU, over a 60-day period. A total of 69 participants were initially screened for eligibility in a double-blind randomized study with a four-arm parallel design; 35 participants were randomized to treatment groups: (1) standard Vitamin D3 1000 IU (STD1000), (2) micellar Vitamin D3 1000 IU (LMD1000), (3) standard Vitamin D3 2500 IU (STD2500), and (4) micellar Vitamin D3 2500 IU (LMD2500). Serum Vitamin D concentrations were determined through calcifediol [25(OH)D] at baseline (=before treatment), at day 5, 10, and 15 (=during treatment), at day 30 (=end of treatment), and at day 45 and 60 (=during follow-up/post treatment). Safety markers and minerals were evaluated at baseline and at day 30 and day 60. The pharmacokinetic parameters with respect to iAUC were found to be significantly different between LMD1000 vs. STD1000: iAUC(5–60): 992 ± 260 vs. 177 ± 140 nmol day/L; p < 0.05, suggesting up to 6 times higher Vitamin D3 absorption of LMD when measured incrementally. During follow-up, participants in the LMD1000 treatment group showed approx. 7 times higher Vitamin D3 concentrations than the STD1000 group (iAUC(30–60): 680 ± 190 vs. 104 ± 91 nmol day/L; p < 0.05). However, no significant differences were found between the pharmacokinetics of the higher dosing groups STD2500 and LMD2500. No significant changes in serum 1,25(OH)2D concentrations or other biochemical safety markers were detected at day 60; no excess risks of hypercalcemia (i.e., total serum calcium > 2.63 mmol/L) or other adverse events were identified. LMD, a micellar delivery vehicle for microencapsulating Vitamin D3 (LipoMicel®), proved to be safe and only showed superior bioavailability when compared to standard Vitamin D at the lower dose of 1000 IU. This study has clinical trial registration: NCT05209425.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholecalciferolDietary SupplementsMicellesBiological AvailabilityHumansPilot ProjectsMaleFemaleDouble-Blind MethodAdultAdministration, OralMiddle AgedYoung AdultCalcifediolVitamin D

Stichwörter der Autor:innen

bioavailabilitycholecalciferoldelivery systemsmicellespharmacokineticssupplementationvitamin D

Substanzen

CholecalciferolMicellesCalcifediolVitamin D

Autor:innen und Institutionen

  • ISURA, Clinical Research, Burnaby, BC V3N4S9, Canada.
  • Factors Group of Nutritional Companies Ltd., Burnaby, BC V3N4S9, Canada.
  • Brix Wellness, Ltd., Victoria, BC V8Z 3E9, Canada.
  • College of Nursing and Health Sciences, Flinders University, Sturt Road, Adelaide, SA 5042, Australia.
  • School of Public Health, Faculty of Health Sciences, Curtin University, Perth, WA 6845, Australia.
  • InovoBiologic Inc., Calgary, AB Y2N4Y7, Canada.

ORCID-Profile: Julia Solnier, Chuck Chang, Yun Chai Kuo, Min Du

Förderung

  • Factors Group of Nutritional Companies provided a research grant for this study.
  • Factors Group of Nutritional Companies

Zitieren

APA

Solnier, J., Chang, C., Zhang, Y., Kuo, Y. C., Du, M., Roh, Y. S., See, J., Brix, J., Gahler, R. J., Green, T., & Wood, S. (2024). A Comparison and Safety Evaluation of Micellar versus Standard Vitamin D3 Oral Supplementation in a Randomized, Double-Blind Human Pilot Study. Nutrients. https://doi.org/10.3390/nu16111573

Vancouver

Solnier J, Chang C, Zhang Y, Kuo YC, Du M, Roh YS, et al. A Comparison and Safety Evaluation of Micellar versus Standard Vitamin D3 Oral Supplementation in a Randomized, Double-Blind Human Pilot Study. Nutrients. 2024. doi:10.3390/nu16111573

BibTeX
@article{Solnier2024,
  author = {Solnier, Julia and Chang, Chuck and Zhang, Yiming and Kuo, Yun Chai and Du, Min and Roh, Yoon Seok and See, Janet and Brix, Jennifer and Gahler, Roland J and Green, Tim and Wood, Simon},
  title = {A Comparison and Safety Evaluation of Micellar versus Standard Vitamin D3 Oral Supplementation in a Randomized, Double-Blind Human Pilot Study},
  journal = {Nutrients},
  year = {2024},
  doi = {10.3390/nu16111573}
}
Kostenlos starten →